---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000025"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T06:20:19.965768+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics amends bylaws to update director nomination procedures, universal proxy rules

## Summary
- Updated advance notice provisions for director nominations, including requirements under Rule 14a-19 and limiting nominees to board seats available.
- Enhanced disclosure requirements for nominating stockholders and nominees, with obligation to update and supplement information.
- Clarified procedures for stockholder meetings, including meeting place, adjournment, notices, conduct, and stockholder lists.
- Conforming edits and other clarifying updates to improve consistency across bylaws.

## SEC filing metadata
- accession: 0001664710-25-000025
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000025/0001664710-25-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000025/kros-20250305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000025
- JSON: https://secwatch.observer/filing/0001664710-25-000025.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.